Norcantharidin anti-angiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 499-503

  Yu, Tao ^a   Hou, Fenggang ^a   Liu, Manman ^a   Zhou, Lihong ^b   Li, Dan ^c   Liu, Jianrong ^a   Fan, Zhongze ^b   Li, Qi ^b  

^a Shanghai Chinese Medical University   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Human colorectal cancer; Norcantharidin; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; FUSED HETEROCYCLIC RINGS; NORCANTHARIDIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; ENZYME IMMUNOASSAY; HUMAN; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLORECTAL NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866438722     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.499     Document Type: Article

References (28)

1. Cao Y (2009). Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal, 2, e1.
2. Chen YJ, Kuo CD, Tsai YM, et al (2008). Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs, 19, 55-64.
3. Chen YJ, Shieh CJ, Tsai TH, et al (2005). Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs, 16, 293-9.
4. Carmeliet P(2005). Angiogenesis in life, disease and medicine. Nature, 438, 932-6.
5. Des Guetz G, Uzzan B, Nicolas P, et al (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer, 94, 1823-32.
6. De Vita F, Orditura M, Lieto E, et al (2004). Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 100, 270-8.
7. Ferrara N(2005). VEGF as a therapeutic target in cancer. Oncology, 69, 11-6.
8. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med, 1, 27-31.
9. Fang Y, Tian SL, Li KQ, et al (1993). Studies on antitumor agents II: synthesis and anticancer activity of dehydrogenated carboncyclic analogs of norcantharidin. Yao Xue Xue Bao, 28, 931-5 (in Chinese).
10. Greenberg JI, Shields DJ, Barillas SG, et al (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature, 456, 809-13.
11. Graziano F, Cascinu S (2003). Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol, 14, 1026-38.
12. Gille H, Kowalski J, Li B, et al (2001). Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem, 276, 3222-30.
13. Heath VL, Bicknell R (2009). Anticancer strategies involving the vasculature. Nat Rev Clin Oncol, 6, 395-404.
14. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
15. Jain RK, Duda DG, Clark JW, et al (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3, 24-40.
16. Kitadai Y (2010). Angiogenesis and lymphangiogenesis of gastric cancer. J Oncol, 2010, 468725.
17. Karamysheva AF (2008). Mechanisms of angiogenesis. Biochemistry (Mosc), 73, 751-62.
18. Kerbel RS (2008). Tumor angiogenesis. N Engl J Med, 358, 2039-49.
19. Mohr B, Illmer T (2005). Structural chromosomal aberrations in the colon cancer cell line HCT 116-results of investigations based on spectral karyotyping. Cytogenet Genome Res, 108, 359-61.
20. Peng C, Liu X, Liu E, et al (2009). Norcantharidin induces HT-29 colon cancer cell apoptosis through the alphavbeta6-extracellular signal-related kinase signaling pathway. Cancer Sci, 100, 2302-8.
21. Pang RW, Poon RT (2006). Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag, 2, 97-108.
22. Quesada AR, Munoz-Chapuli R, Medina MA (2006). Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev, 26, 483-530.
23. Rodrigo JP, Cabanillas R, Chiara MD, et al (2009). Prognostic significance of angiogenesis in surgically treated supraglottic squamous cell carcinomas of the larynx. Acta Otorrinolaringol Esp, 60, 272-7 (in Spanish).
24. Svagzdys S, Lesauskaite V, Pavalkis D, et al (2009). Microvessel density as new prognostic marker after radiotherapy in rectal cancer. Bmc Cancer, 9, 95.
25. Shibuya M, Claesson-Welsh L (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Res, 312, 549-60.
26. Tanigawa N, Amaya H, Matsumura M, et al (1997). Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res, 57, 1043-6.
27. Veikkola T, Alitalo K (1999). VEGFs, receptors and angiogenesis. Semin Cancer Biol, 9, 211-20.
28. Wang GS (1989). Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol, 26, 147-62.